Skip to content
doc.socialdoc.social

Listening

Episode

The Niche Episode 011 – AstraZeneca, Satsuma Pharmaceuticals, and Orasis Pharmaceuticals

The recording for this episode is no longer available from its publisher. Everything else about it is kept here.

This week, vaccines and shark statistics, are noses the ultimate pipedream, and eye drops to replace eye-glasses.




Sponsors

https://www.thescopemethod.com

Story References

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html

https://www.globenewswire.com/news-release/2020/09/10/2091685/0/en/Satsuma-Pharmaceuticals-Announces-Topline-Results-from-EMERGE-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine.html

https://www.orasis-pharma.com/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.